
Share
DOMINATE the 2027 TSITE Exam with our FREE podcast review series, covering 28 high-yield topics.
Enjoy this sample episode from the course.
This podcast series was designed specifically to help you prepare for the Thoracic Surgery Directors Association In-Training (TSITE) Exam. All you need is a Behind the Knife account. Once registered, you will see the content in your Library. Track your progress, take notes, and access the material on our iOS or Android app.
Get instant course access: https://behindtheknife.org/premium/tsite-2027-exam-review
Additional Resources:
- Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-review
- Cardiothoracic Oral Board Simulator: https://behindtheknife.org/oral-board/simulator
Welcome back to Behind the Knife, TSITE edition. Today, we're tackling lung cancer staging. I'm Abby Benkard, a cardiothoracic surgery resident at Duke, and I have Dr.
Patel here with me today. Hey, Abby. I- yeah, I am Kunal Patel. I am one of the thoracic surgeons and lung transplant surgeons at Duke University, and I too am
very glad to be here. Lung cancer staging, which again was what we're talking about today, determines whether a patient gets a surgical resection, systemic therapy, radiation, or any combination of all three.
All right, let's go through it. Before staging, we should recognize how these patients present because
symptoms themselves carry staging implications. Two-thirds of patients have symptoms from locally advanced or metastatic disease at the time of diagnosis. So Abby, how do you organize presentation for the boards?
I think in three symptom buckets. Number one, pulmonary; number two, extrapulmonary
thoracic; and three, extrathoracic. So pulmonary symptoms to think about are cough, dyspnea, hemoptysis, wheeze or stridor, and post-obstructive pneumonia. For the extrapulmonary thoracic bucket, that's really focusing on local invasion, so things like chest wall pain.
For example, a
Pancoast tumor can give the triad of shoulder pain, C8 to T1 radicular arm pain, and Horner syndrome., Also if there's recurrent laryngeal nerve involvement from the tumor, that can cause hoarseness. Other extrapulmonary thoracic symptoms include things like phrenic nerve palsy and SVC syndrome.
And then lastly,
extrathoracic symptoms usually indicate metastatic disease, so thinking brain, bone, liver, adrenal involvement symptoms, or a paraneoplastic syndrome. Yeah. Paraneoplastic pairings are classic board fodder, as I'm sure everyone who's listening knows. But give us the ones
that you have to know cold.
Yeah. So these can be almost guaranteed points if you just remember these associations. So SIADH and ectopic ACTH, usually points to small cell lung cancer. Lambert in myasthenic syndrome, this develops from antibodies to voltage-gated calcium channels. This is
also small cell. Um, remember, this is proximal weakness that transiently improves with use, as compared to myasthenia gravis, which, is weakness that fatigues.
And then lastly, hypercalcemia from PTHrP, usually associated with squamous cell. Remember, the paraneoplastic syndrome can precede the
radiographic tumor by months to years, so it can often herald the malignancy. And increasingly, our patients are arriving to clinic to be seen for incidental nodules found on imaging for, you know, a number of reasons.
Define for me pulmonary nodules, and let me know what,
uh, malignancy risk features would-- you would think are concerning Sure. A solitary pulmonary nodule is under three centimeters and surrounded by parenchyma. Um, when you're evaluating these on imaging, features that push towards malignancy include spiculated margins, upper lobe
location, a history of smoking, and malignant growth rate, so a doubling time between thirty and four hundred days.
When you're evaluating these nodules, reassuring features include smooth margins, benign calcification patterns, and a two-year stability for solid nodules. The other thing to evaluate is the density. So pure
ground-glass nodules are low risk, but part solid nodules carry the highest malignancy risk, and a growing solid component of those can signal invasion.
Correct. And we use the Fleischner guidelines to determine next steps and follow-up for incidentally detected nodules. Abby, go through some of the quick hits from the Fleischner
guidelines. Definitely. And I have seen the Fleischner guidelines show up on the TSITE. So these are some guidelines also just to commit to memory and have in your back pocket.
So for solid nodules, I typically think about this in two ways, either single versus multiple and then low risk
versus high risk patient.
So for a single solid nodule in a low risk patient, a nodule under six millimeters needs no routine follow-up at all. Between six and eight millimeters, get a CT scan at six to twelve months, then consider one more at eighteen to twenty-four months if it's stable. Above eight millimeters, the pretest probability is high enough that you
escalate.
So consider a CT scan at three months, a PET CT or tissue sampling outright. And then for high risk patients, the only difference is you can elect to get an optional CT scan at twelve months for nodules less than six millimeters. And then for our category of multiple nodules, you wanna use the most suspicious one to drive management
decisions.
And the follow-up interval shifts slightly earlier for the intermediate and larger sizes since you're aggregating risk across multiple lesions And for sub-solid nodules? A single pure ground-glass nodule under six millimeters, again, needs no routine follow-up. At six millimeters or larger, it gets a CT scan at six to
12 months to confirm persistence, and if it is persistent, get a CT scan every two years out to five years.
Then a single part solid nodule under six millimeters, again, no routine follow-up, although the NCCN, recommends adding an additional optional CT scan at 12 months for high-risk
patients. Remember, a lesion can't really be called part solid until it's at least six millimeters. So at six millimeters or larger, get a CT scan at three to six months to confirm persistence.
Um, if it's still present and the solid component stays under six millimeters, then annual CT scan for five years. But once the solid component
reaches six millimeters or more, the nodule is highly suspicious, so consider a PET CT or biopsy, um, and in a fit patient, evaluate them for, uh, candidacy for a resection.
Yeah, great. And so you said six millimeters a lot throughout all of that, which I think is the important number for folks to keep in their
brain. Um, once those nodules hit six millimeters, then you need to start asking more questions about your ground glass versus solid versus part solid, and then the imaging, uh, and those sorts of things.
But again, six millimeters is a good number to commit to memory. All right. The-- That was a lot of
information. Uh, we are gonna have a companion table that may hopefully streamline it if people want to access that. As an important aside, these Fleischner guidelines are different from the Lung-RADS system, uh, if you see those, uh, which are used for nodules detected on lung cancer screening scans.
Now,
for screening, uh, you need to know who qualifies, uh, and there are a few different guidelines with slightly different criteria. But the NCCN guidelines recommend an annual low-dose CT scan for patients that are fifty years old or older with at least twenty pack years of smoking history. And under these
guidelines, former smokers are eligible regardless of how long it's been since they quit.
A-and it's worth knowing, obviously, those guidelines are different from the current guidelines by the US Preventative Services Task Force, um, which are, are based off of the lung cancer screening trials.
We talk
more about those trials and those guidelines in our episode on the hallmark thoracic trials. So hop over to that podcast if you wanna learn more about all of the lung cancer screening guidelines. Okay. Moving on, let's get to the
backbone of this episode. Abby, why don't we go through the T, N, and M stages for non-small cell lung cancer and how those, uh, stages collapse down into the staging groups.
Sounds good. So I'll start with T stage. T is focused on size of the tumor, and
this is, decided in one centimeter increments. So by size, T1 is three centimeters or less. Um, this can be further subdivided. T1A is a tumor up to one centimeter, T1B is one to two centimeters, T1C is two to three centimeters.
And then T2 is a
tumor three to five centimeters in size. Again, this is further subdivided, where T2A is three to four, T2B is four to five, and then T3 is five to seven centimeters, and T4 is greater than seven centimeters, um, just looking at size criteria.
Uh, exactly. So there are also some considerations in addition to the size of the tumor.
Tumors, uh, that are less than or equal to four centimeters can be upstaged to T2A if there's visceral pleural invasion, uh, i-into an adjacent lobe, uh, i-or if there is involvement
of the main bronchus. And a tumor can be upstaged to T3 if it's less than seven centimeters but has any of the following: So invasion into the parietal pleura, chest wall, pericardium, phrenic nerve, azygos, or any thoracic nerve roots.
And tumors of any size are upgraded to
T4 if there's invasion into mediastinum, thymus, trachea, carina, recurrent laryngeal nerve, heart, great vessels, subclavian vessels, vertebral body, spinal canal, or brachial plexus. So distilling all of that down, if the tumors are invading,
probably is gonna be a higher stage than what the size would indicate.
Great. And Dr. Patel, can you talk a little bit about if there are multiple nodules present? I think it can get kind of confusing to determine what the accurate T stage is for those multiple nodules.
Yeah, it, it can get confusing, and we spend a significant amount of time at our tumor board talking
about this very scenario. It, it ultimately it comes down to whether a nodule is in the same lobe and what the histology is. So a separate nodule of the same histology in the same lobe is T3. If it, it's in a different ipsilateral lobe again, with the
same histology, then it's T4.
Uh, and if it's in a contralateral lung, it's M1A. Again, that's all under the, the presupposition that it's of the same histology and that it's likely a metastatic or satellite nodule of the same, uh of the
same lesion. Now, if it's a separate histology under the microscope, then we would call those synchronous primary cancers and they have distinct molecular histologic features, and that was confirmed by the pathologist.
These are staged separately with their own TNM, and ultimately, we will
go with the one that is the largest, most aggressive to determine the patient's overall cancer staging. So let's move on to the nodal staging now. Yeah. So N staging is based on anatomic location of nodal involvement and can
really be pivotal for determining whether a patient's tumor is resectable.
So N0, um, means there is no nodal involvement. N1 means there is ipsilateral, peribronchial, intrapulmonary, or hilar involvement, so stations ten through fourteen. N2 is ipsilateral mediastinal or
subcarinal involvement, so station seven and the ipsilateral stations two through nine. And then N3 is contralateral mediastinal or hilar nodal involvement or any positive node in scalene or supraclavicular station.
Remember, N3 is generally unresectable. Right. I-I'm sure most of the people that
are listening will know this by now, but, you know, the easy way to remember that N1 stations are double digit, N2 stations are single digit, uh, and that's just, you know, how I keep it straight in my brain.
So N2 is now split, in the ninth edition. N2a is involvement of a
single ipsilateral mediastinal or subcarinal station. N2b is involvement of multiple stations. So systematic nodal sampling is needed for assigning the correct stage.
NCCN guidelines state that once N2 disease is found, the pathologic evaluation must
include the subcarinal station and contralateral nodes, and document the number of stations involved before making any final treatment decisions. All right, Abby, walk us now through the M staging. Yeah. So M staging, um, obviously looking at whether there is metastatic
disease present or not. So M0 is, um, there's no distant metastasis, and then M1 signifies there is presence of distant metastasis. M1 is further subdivided into 1A, uh, with intrathoracic metastasis, so, involvement of a contralateral lung nodule, a malignant pleural or
pericardial effusion, or pericardial nodules.
M1B is presence of a single extrathoracic metastasis, so this is the oligometastatic category. Um, and then finally, M1C is presence of multiple extrathoracic metastases. Now let's collapse all of
this information into the stage groups. So roughly, um, I can collapse this into stage I applies to node-negative small tumors.
Stage II brings in N1 or larger T stages. Stage III is the heterogeneous locally advanced group that
includes N2, N3, and T4 disease. And then stage IV is easy to remember. It's any M1, disease. And I think really when thinking about making treatment decisions, the most important survival differentiation is when jumping from resectable stage I and II disease to N2 stage III
disease.
And we've included a table in our companion document that will list all of the, uh, stages and, and what TNM, components go into each of those. Yeah, and you can reference that or you can also just pull up the NCCN guidelines and, I don't know, tape them above your bed at night. Hopefully, some of it'll absorb in.
What goes into the staging workup, Abby? How do you determine clinical TNM staging? Yeah. So now that we've gone through the definition of the TNM, how do we actually get there? Um, usually start with a CT of chest and upper abdomen. To evaluate for nodal involvement, um, you're looking at the CT scan of the chest and
any node with a size over one centimeter in the short axis defines adenopathy. You can't really stage the mediastinum alone with the CT scan if there is evidence of adenopathy, so you would wanna add in a PET-CT scan.
And the PET-CT has a really strong negative predictive value. So in
early-stage non-small cell lung cancer, a PET negative mediastinum has a negative predictive value around ninety-five percent, so you can skip invasive staging. But if you do have PET positive mediastinal nodal disease, then that node should be biopsied.
For nodal tissue diagnosis, cervical mediastinoscopy is the gold
standard, um, which allows you to access stations 2R, 2L, 4R, 4L, and 7. However, in today's day and age, I think EBUS has largely replaced cervical mediastinoscopy, um, 'cause it can reach the same stations plus also get you stations ten and 11 and can be done, you know,
minimally invasively.
A negative EBUS in a node that is suspicious on CT or PET scan should be confirmed with mediastinoscopy, um, and get a tissue diagnosis prior to proceeding to the operating room. Yeah. Summarizing all of that i-if there is a node that looks suspicious either on
PET or on, uh, on CT, meeting that size criteria of one centimeter, um, they should just get invasive mediastinal staging.
Obviously, if the tumor meets size criteria, being T2 or greater, should get invasive mediastinal staging. Um, but if all that stuff looks normal preoperatively, you can proceed to surgery with the segment
or lobe or wedge, whatever you're gonna do, and feel comfortable, um, that the, the mediastinum is not going to surprise you.
All right, who needs a brain MRI? So I think this has changed a little bit from the eighth edition to the ninth edition. Um, so currently patients with stage two to four non-small
cell lung cancer should get a brain MRI, and, um, now it's optional for stage 1B. Also obviously indicated for anyone with neurologic symptoms.
And then for small cell lung cancer, every patient should get a brain MRI. All right, here's a little bit of gray area. What do you do if you have an operable patient with an indeterminate
nodule and a non-diagnostic biopsy? Yeah. So a negative CT-guided or bronchoscopic biopsy doesn't rule out cancer as for small lesions the sensitivity can fall and drop off.
And a non-diagnostic result in an operable surgically fit patient should proceed to
resection, not repeat biopsy, especially if there's a high suspicion for malignancy based on its appearance on, um, preoperative workup. Dr. Patel, how do you approach restaging patients after they've received induction therapy?
Typically what I do is just get a CT with or without a PET uh, just to
exclude progression or new metastatic disease okay. Now take us through small cell lung cancer staging, Abby Yeah. So the TNM algorithm does apply to small cell in the ninth edition and is used for the rare early-stage surgical candidate.
Um, but the
VALG system is, uh, often used as well. Um, this divides disease into limited stage and extensive stage, um, to help guide treatment decisions. So limited stage disease is confined to just one lung and its nodes, whereas extensive stage disease has spread more widely beyond one lung And because
small cell metastasizes early, everyone gets the full workup.
So a PET-CT, a brain MRI, regardless of how small the primary looks, um, because roughly two-thirds of those patients are gonna present with extensive stage disease. And since we're thoracic surgeons, it's good to know
which small cell patients will get surgery So we play a role in limited stage disease a clinical T1, T2, N0 tumor.
Um, it's typically a peripheral nodule that can be resected. These patients should get a mediastinoscopy first to confirm N0 disease, then lobectomy, um, and
then they'll proceed to get adjuvant platinum etoposide. Um, any resected small cell gets adjuvant chemotherapy. Um, the thing to remember here is the historical MRC trial that demonstrated surgery was inferior to systemic therapy really predated modern staging and chemotherapy.
So Don't exclude surgery in a
patient who presents with T1 to T2 N0 disease.
And then remember node-positive disease is treated with concurrent chemoradiation, not surgery.
All right. That's everything that we have for lung cancer staging. Thanks everyone for listening, and as always, remember to dominate the
day.
More from General
Inside the ACGME Rewrite: Trainees and Program Directors on the Proposed Common Program Requirements
EP. 1097 · NOV. 19, 2026 · 42 MIN
Colorectal Emergencies Crossover: Navigating Diverticulitis, Gunshot Wounds to the Pelvis, and Toxic Megacolon
EP. 1096 · NOV. 16, 2026 · 53 MIN
Clinical Informatics for Surgeons, Episode 3: AI in the OR and Beyond; Machines That See, Read, and Act
EP. 1094 · NOV. 9, 2026 · 35 MIN
Clinical Informatics for Surgeons, Episode 2: Legal Discovery and Cybersecurity When a Case Goes Wrong
EP. 1093 · NOV. 5, 2026 · 33 MIN
Clinical Informatics for Surgeons, Episode 1: What Is Clinical Informatics, and Why Should Surgeons Care?
EP. 1092 · NOV. 2, 2026 · 29 MIN
